Source: European Medicines Agency (EU) Revision Year: 2022 Publisher: Gilead Sciences Ireland UC, Carrigtohill, County Cork, T45 DP77, Ireland
Sunlenca 464 mg solution for injection.
Pharmaceutical Form |
---|
Solution for injection (injection). Clear, yellow to brown solution. |
Each single-dose vial contains lenacapavir sodium equivalent to 463.5 mg of lenacapavir in 1.5 mL.
For the full list of excipients, see section 6.1.
Active Ingredient | Description | |
---|---|---|
Lenacapavir |
Lenacapavir is a multistage, selective inhibitor of HIV-1 capsid function that directly binds to the interface between capsid protein (CA) subunits. Lenacapavir inhibits HIV-1 replication by interfering with multiple, essential steps of the viral lifecycle, including capsid-mediated nuclear uptake of HIV-1 proviral DNA, virus assembly and release, and capsid core formation. |
List of Excipients |
---|
Macrogol (E1521) |
Sunlenca injection is packaged in a dosing kit containing:
Gilead Sciences Ireland UC, Carrigtohill, County Cork, T45 DP77, Ireland
EU/1/22/1671/02
Drug | Countries | |
---|---|---|
SUNLENCA | Austria, Estonia, France, Croatia, Ireland, Israel, Italy, Lithuania, Romania, United Kingdom |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.